Pharmacogenetics in Neuroblastoma : What Can Already Be Clinically Implemented and What Is Coming Next?
Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 22(2021), 18 vom: 10. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olivera, Gladys G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 22.10.2021 Date Revised 03.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms22189815 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331175843 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331175843 | ||
| 003 | DE-627 | ||
| 005 | 20240403233818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms22189815 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM331175843 | ||
| 035 | |a (NLM)34575974 | ||
| 035 | |a (PII)9815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olivera, Gladys G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics in Neuroblastoma |b What Can Already Be Clinically Implemented and What Is Coming Next? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2021 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SNP (single nucleotide polymorphism) | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a clinical implementation guidelines | |
| 650 | 4 | |a drug label | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Urtasun, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Sendra, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Aliño, Salvador F |e verfasserin |4 aut | |
| 700 | 1 | |a Yáñez, Yania |e verfasserin |4 aut | |
| 700 | 1 | |a Segura, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Gargallo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Berlanga, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Castel, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Adela |e verfasserin |4 aut | |
| 700 | 1 | |a Herrero, María José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 18 vom: 10. Sept. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:18 |g day:10 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22189815 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 18 |b 10 |c 09 | ||